As of 2024-12-15, the EV/EBITDA ratio of AnaptysBio Inc (ANAB) is -1.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AnaptysBio's latest enterprise value is 282.82 mil USD. AnaptysBio's TTM EBITDA according to its financial statements is -177.10 mil USD. Dividing these 2 quantities gives us the above AnaptysBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 15.5x | 13.8x |
| Forward P/E multiples | 12.8x - 15.4x | 15.0x |
| Fair Price | (68.43) - (83.33) | (77.51) |
| Upside | -539.0% - -634.5% | -597.2% |
| Date | EV/EBITDA |
| 2024-12-13 | -1.60 |
| 2024-12-12 | -1.50 |
| 2024-12-11 | -1.58 |
| 2024-12-10 | -2.89 |
| 2024-12-09 | -2.85 |
| 2024-12-06 | -3.18 |
| 2024-12-05 | -2.98 |
| 2024-12-04 | -3.06 |
| 2024-12-03 | -2.70 |
| 2024-12-02 | -3.11 |
| 2024-11-29 | -3.21 |
| 2024-11-27 | -3.23 |
| 2024-11-26 | -3.26 |
| 2024-11-25 | -3.06 |
| 2024-11-22 | -2.74 |
| 2024-11-21 | -2.56 |
| 2024-11-20 | -2.41 |
| 2024-11-19 | -2.35 |
| 2024-11-18 | -2.16 |
| 2024-11-15 | -2.18 |
| 2024-11-14 | -2.38 |
| 2024-11-13 | -2.48 |
| 2024-11-12 | -2.61 |
| 2024-11-11 | -2.77 |
| 2024-11-08 | -2.58 |
| 2024-11-07 | -2.61 |
| 2024-11-06 | -2.73 |
| 2024-11-05 | -2.33 |
| 2024-11-04 | -2.34 |
| 2024-11-01 | -2.64 |
| 2024-10-31 | -2.63 |
| 2024-10-30 | -2.73 |
| 2024-10-29 | -4.21 |
| 2024-10-28 | -4.16 |
| 2024-10-25 | -4.42 |
| 2024-10-24 | -4.45 |
| 2024-10-23 | -4.89 |
| 2024-10-22 | -4.96 |
| 2024-10-21 | -5.00 |
| 2024-10-18 | -4.93 |
| 2024-10-17 | -4.96 |
| 2024-10-16 | -4.88 |
| 2024-10-15 | -4.63 |
| 2024-10-14 | -4.89 |
| 2024-10-11 | -4.63 |
| 2024-10-10 | -4.42 |
| 2024-10-09 | -4.32 |
| 2024-10-08 | -4.48 |
| 2024-10-07 | -4.59 |
| 2024-10-04 | -4.76 |